Skip to content
Study details
Enrolling now

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

Gagan Joshi
NCT IDNCT06853665ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

196

Study length

about 4 years

Ages

8–18

Locations

1 site in MA

What this study is about

Researchers are testing a treatment called Adderall XR (mixed salts amphetamine) to see if it helps people with ADHD and autism. The trial will last 1461 days, involving brain imaging scans at MIT. Participants will take either Adderall XR or a placebo for 10 weeks, completing questionnaires and virtual visits.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Adderall XR (mixed salts amphetamine)
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

stimulant (Amphetamine/dextroamphetamine (CNS stimulant combination)), NERVOUS SYSTEM

Endpoints

Secondary: Pre and post treatment changes in ASD core symptoms on Social Responsiveness Scale 2 (SRS-2)

Body systems

Psychiatry / Mental Health